首页> 外文OA文献 >Correction to “Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms”

【2h】

Correction to “Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms”

机译：“发现有效和口服有效的双janus激酶2 / flt3抑制剂治疗急性髓性白血病和myeloproiferative neoplasms的校正”

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Tao Yang; Mengshi Hu; Wenyan Qi; Zhuang Yang; Minghai Tang; Jun He; Yong Chen; Peng Bai; Xue Yuan; Chufeng Zhang; Kongjun Liu; Yulin Lu; Mingli Xiang; Lijuan Chen;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献
专利

1. Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms (vol 62, pg 10305, 2019) [J] . Yang Tao, Hu Mengshi, Qi Wenyan, Journal of Medicinal Chemistry . 2020,第3期

机译：发现有效和口服有效的双janus激酶2 / flt3抑制剂，用于治疗急性髓性白血病和myeloproiferative肿瘤（Vol 62，Pg 10305,2019）
2. Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms [J] . Yang Tao, Hu Mengshi, Qi Wenyan, Journal of Medicinal Chemistry . 2019,第22期

机译：发现有效和口服有效的双janus激酶2 / flt3抑制剂，用于治疗急性髓性白血病和myeloproiferative肿瘤
3. Identification of Pyrrolo[2,3-d]pyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia [J] . Yuan Xue, Chen Yong, Zhang Wanhua, Journal of Medicinal Chemistry . 2019,第8期

机译：鉴别吡咯并[2,3-D]嘧啶的衍生物作为有效和口服有效的FMS酪氨酸受体激酶3（FLT3）抑制剂，用于治疗急性髓性白血病
4. Treatment of Acute Myelogenous Leukemia in a Mexican Pediatric Hospital [C] . Mario 1. Ortiz, Ildefonsa Hemandez-Rubio, Deyanira Cortes-AIva, Western Pharmacology Society . 2010

机译：墨西哥儿科医院急性髓性白血病治疗
5. Comparison of FLT3 Inhibitors with the Standard Treatment for FLT3-ITD Mutated Acute Myeloid Leukemia [D] . Argetsinger, Stephanie. 2018

机译：FLT3抑制剂对FLT3-ITD突变急性髓性白血病标准治疗的比较
6. Optimization of Imidazo45-bpyridine-Based Kinase Inhibitors: Identification of aDual FLT3/AuroraKinase Inhibitor as an Orally Bioavailable Preclinical DevelopmentCandidate for the Treatment of Acute Myeloid Leukemia [O] . Vassilios Bavetsias, *, Simon Crumpler, -1

机译：基于咪唑并45-b吡啶的激酶抑制剂的优化：双FLT3 / Aurora激酶抑制剂作为口服生物可用的临床前开发治疗急性髓性白血病的候选人
7. Identification of Pyrrolo2,3dpyrimidine-Based Derivatives as Potent and Orally Effective Fms-like Tyrosine Receptor Kinase 3 (FLT3) Inhibitors for Treating Acute Myelogenous Leukemia [O] . -1

机译：吡咯的鉴定基于嘧啶的衍生物作为有效和口服有效的FMS样酪氨酸受体激酶3（FLT3）抑制剂，用于治疗急性髓性白血病

Correction to “Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms”

著录项

引文网络

相似文献

相关主题

期刊订阅